Blood Biomarker in Early Parkinson’s Disease

Overview

Currently, there are no cures or disease modifying therapies for Parkinson's disease (PD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for PD. Several detection parameters will be assessed through enrollment of Parkinson's patients and age matched healthy volunteers over 50 years of age to learn more about the analytical process and biological variability.

Full Title of Study: “Blood Biomarker in Early Parkinson’s Disease”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: January 7, 2019

Arms, Groups and Cohorts

  • Healthy Volunteers
  • Parkinson’s Disease

Clinical Trial Outcome Measures

Primary Measures

  • Biological marker of Parkinson’s disease
    • Time Frame: Day 1
    • Test for biological marker of Parkinson’s disease, mtDNA damage

Participating in This Clinical Trial

Inclusion

Age matched to PD patient Parkinson's Disease Patients:

  • 50 years and older
  • PD patient who is seen at the Duke Movement Disorders Center
  • Early PD diagnosis (Hoehn and Yahr scale ≤ 3)
  • Non-smoking
  • No cancer treatment in the last 5 years
  • Able to read and speak English

Healthy Control Participants:

  • 50 years and older
  • Non-smoking
  • No cancer treatment in the last 5 years
  • Able to read and speak English

Exclusion Criteria

Parkinson's Disease Patients:

  • Known additional neurological disease
  • Clinical trial intervention within the last 6 months

Healthy Control Participants:

  • Neurological degenerative diseases (such as Parkinson's, Alzheimer's or Huntington's)
  • Clinical trial intervention within the last 6 months

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Duke University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Laurie Sanders, PhD, Principal Investigator, Duke University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.